NCT06525220: A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
- State
- Under way
- Phase
- Phase 3
- People
- 699 taking part
- Started
- 25 Sep 2024
- Primary completion
- Jan 2028
- Arms
- Petosemtamab + Pembrolizumab
- Results
- None posted
- 29 Jul 2024: Trial registered
- 25 Sep 2024: Trial started